GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xiangxue Pharmaceutical Co Ltd (SZSE:300147) » Definitions » Cash-to-Debt

Xiangxue Pharmaceutical Co (SZSE:300147) Cash-to-Debt : 0.05 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Xiangxue Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Xiangxue Pharmaceutical Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.05.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Xiangxue Pharmaceutical Co couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Xiangxue Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

SZSE:300147' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05   Med: 0.22   Max: 1.66
Current: 0.05

During the past 13 years, Xiangxue Pharmaceutical Co's highest Cash to Debt Ratio was 1.66. The lowest was 0.05. And the median was 0.22.

SZSE:300147's Cash-to-Debt is ranked worse than
96.09% of 1508 companies
in the Biotechnology industry
Industry Median: 6.505 vs SZSE:300147: 0.05

Xiangxue Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Xiangxue Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Xiangxue Pharmaceutical Co Cash-to-Debt Chart

Xiangxue Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.16 0.08 0.07 0.06

Xiangxue Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.05 0.05 0.06 0.05

Competitive Comparison of Xiangxue Pharmaceutical Co's Cash-to-Debt

For the Biotechnology subindustry, Xiangxue Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xiangxue Pharmaceutical Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xiangxue Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Xiangxue Pharmaceutical Co's Cash-to-Debt falls into.



Xiangxue Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Xiangxue Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Xiangxue Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xiangxue Pharmaceutical Co  (SZSE:300147) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Xiangxue Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Xiangxue Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Xiangxue Pharmaceutical Co (SZSE:300147) Business Description

Traded in Other Exchanges
N/A
Address
No 2 Jinfeng Road , Science City, Guangzhou Economic and Technological Development Z, Guangzhou, CHN, 510663
Xiangxue Pharmaceutical Co Ltd is a China-based company engages in the manufacture and distribution of pharmaceutical products. Its diversified healthcare portfolio includes Chinese Herbal Slices, TCM, Life Science, Biomedical Engineering health solutions (food and beverage), healthcare supplements and so on.
Executives
Huang Wei Hua Supervisors
Tan Wen Hui Director
Kang Zhi Ying Executives
Ceng Lun Executives
Liu Yan Executives
Lu Feng Executives
Xu Li Secretary, Director
Mo Zi Yu Supervisors
Mai Zhen Jiang Supervisors
Wang Yong Hui Directors, executives
He Tao Executives
Fang Wei Min Supervisors
Huang Bin Directors, Directors, and Executives
Wu Jun Executives
Chen Wen Jin Executives

Xiangxue Pharmaceutical Co (SZSE:300147) Headlines

No Headlines